Allergic rhinitis: Continuous or on demand antihistamine therapy?

Journal of Investigational Allergology and Clinical Immunology

Volumn 17, Issue SUPPL.2, 2007, Pages 21-27

  Montoro, Javier ^a   Sastre, J ^b   Jauregui I ^c   Bartra, J ^d   Davila I ^e   Del Cuvillo, A ^f   Ferrer, M ^g   Mullol, J ^d   Valero, A ^d  

^a HOSPITAL DE LA PLANA   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c HOSPITAL DE BASURTO   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f Clinica Dr Lobaton   (Spain)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Allergic rhinitis; Antihistamines; Continuous treatment; Minimal persistent inflammation; Priming effect; Treatment upon demand

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; VASCULOTROPIN; ANTIINFLAMMATORY AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST;

ALLERGIC RHINITIS; CELL INFILTRATION; CLINICAL TRIAL; DRUG EFFICACY; ENVIRONMENTAL EXPOSURE; HUMAN; LUNG ALVEOLUS EPITHELIUM; NOSE CONGESTION; PATHOPHYSIOLOGY; POLLUTANT; QUALITY OF LIFE; REVIEW; RHINOCONJUNCTIVITIS; ANIMAL; CHRONIC DISEASE; DRUG ADMINISTRATION; IMMUNOLOGY; PERENNIAL RHINITIS; PRACTICE GUIDELINE; PSYCHOLOGICAL ASPECT; RESPIRATORY TRACT ALLERGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RESPIRATORY HYPERSENSITIVITY; RHINITIS, ALLERGIC, PERENNIAL;

EID: 38949099097     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Bousquet J, van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(Suppl. 5):S147-S334.
2. Bachert C, van Cauwenberge P, Olbrecht J, van Schoor J. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy. 2006;61:693-98.
3. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32:489-98.
4. Walsh GM. The clinical relevance of the anti-inflammatory properties of antihistamines. Allergy. 2000;55:53-61.
5. Bousquet J, van Cauwenberge P, Ait Khaled N, Bachert C, Baena-Cagnani CE, Bouchard J, Bunnag C, Canonica GW, Carlsen KH, Chen YZ, Cruz AA, Custovic A, Demoly P, Dubakiene R, Durham S, Fokkens W, Howarth P, Kemp J, Kowalski ML, Kvedariene V, Lipworth B, Lockey R, Lund V, Mavale-Manuel S, Meltzer EO, Mullol J, Naclerio R, Nekam K, Ohta K, Papadopoulos N, Passalacqua G, Pawankar R, Popov T, Potter P, Price D, Scadding G, Simons FE, Spicak V, Valovirta E, Wang DY, Yawn B, Yusuf O; GA2LEN. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy. 2006;61:1086-96.
6. Jutel M, Blaser K, Akdis CA. Histamine in chronic allergic responses. J Investig Allergol Clin Immunol. 2005;15:1-8.
7. Ghosh AK, Hirasawa N, Ohtsu H, Watanabe T, Ohuchi K. Defective angiogenesis in the inflammatory granulation tissue in histidine decarboxylase-deficient mice but not in mast cell-deficient mice. J Exp Med. 2002;195:973-82.
8. Kay AB. Asthma and inflammation. J Allergy Clin Immunol. 1991;87:893-910.
9. Ciprandi G, Buscaglia S, Pesce G, Pronzato C, Ricca V, Parmiani S, Bagnasco M, Canonica GW. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol.1995;96:971-9.
10. Canonica GW, Ciprandi G, Pesce GP, Buscaglia S, Paolieri F, Bagnasco M. ICAM-1 on epithelial cells in allergic subjects: a hallmark of allergic inflammation. Int Arch Alergy Immunol.1995;107:99-102.
11. Ciprandi G, Ricca V, Passalacqua G, Truffelli T, Bertolini C, Fiorino N, Riccio AM, Bagnasco M, Canonica GW. Seasonal rhinitis and azelastine: Long or short term treatment. J Allergy Clin Immunol.1997;99:301-7.
12. Ricca V, Landi M, Ferrero P, Bairo A, Tazzer C, Canonica GW, Ciprandi G. Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol.1999;104:54-7.
13. Whiteman SC, Bianco A, Knight RA, Spiteri MA. Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion molecule-1 (ICAM-1) receptor to promote epithelial cell infectivity. J Biol Chem. 2003;278:11954-61.
14. Márquez F, Sastre J, Hernández G, Cenjor C, Sánchez-Hernández JM, Sánchez J, Gutiérrez R, Sanabria J. Nasal hyperreactivity to methacholine measured by acoustic rhinometry in asymptomatic allergic and perennial non-allergic rhinitis. Am J Rhinology. 2000;14:251-6.
15. Ciprandi G, Tosca MA, Fasce L. Allergic children have more numerous and severe respiratory infections than non-allergic children. Pediatr Allergy Immunol. 2006;17:389-91.
16. Jinquan T, Reimert CM, Deleuran B, Zachariae C, Simonsen C, Thestrup-Pedersen K. Cetirizine inhibits the in vitro and ex vivo chemotactic response of T lymphocytes and monocytes. J Allergy Clin Immunol.1995;95:979-86.
17. Matsubara M, Tamura T, Ohmori K, Hasegawa K. Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+-dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B signal cascades. Biochem Pharmacol. 2005;69:433-49.
18. Johnson GL and Lapadat R.Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298: 1911-2.
19. Tak PP and Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest. 2001;107:7-11.
20. Schmidt J, Kaufmann B, Lindstaedt R, Szelenyi I. Inhibition of chemiluminescence in granulocytes and alveolar macrophages by azelastine. Agents Actions.1990;31:229-36.
21. Umeki S. Effects of anti-allergic drugs on human neutrophil superoxide-generating NADPH oxidase. Biochem Pharmacol. 1992;43:1511-20.
22. Xia Q, Yang S, Zhang SQ, Chen B, Wang DB, Zhu QX, Wang Y, Yan KL, He PP, Zhang XJ. The effect of mizolastine on expression of vascular endothelial cell growth factor, tumor necrosis factor-alpha and keratinocyte-derived chemokine in murine mast cells, compared with dexamethasone and loratadine. Clin Exp Dermatol. 2005;30:165-70.
23. Mullol J, Roca-Ferrer J, Alobid I, Pujols L, Valero A, Xaubet A, Bernal-Sprekelsen M, Picado C. Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival. Clin Exp Allergy. 2006;36:52-8.
24. Ciprandi G, Buscaglia S, Pronzato C, Benvenuti C, Cavalli E, Bruzzone M, Canonica GW. Oxatomide reduces inflammatory events induced by allegen specific conjunctival challenge. Ann Allergy Asthma Immunol. 1995;75:446-52.
25. Fasce L, Ciprandi G, Pronzato C, Cozzani S, Tosca MA, Grimaldi I, Canonica GW. Cetirizine reduces ICAM-1 expression on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite allergic asthma. Int Arch Allergy Immunol.1996;109:272-6.
26. Ciprandi G, Pronzato C, Ricca V, Varese P, Del Giacco GS, Canonica GW. Terfenadine exerts anti-allergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy. Clin Exp Allergy. 1995;25:871-8.
27. Ciprandi G, Pronzato C, Passalacqua G, Ricca V, Grogen J, Mela GS, Varese P, Bertolini C, Bagnasco M, Canonica GW. Topical azelastine reduces eosinophil activation and ICAM-1 expression on nasal epithelial cells: an anti-allergic activity. J Allergy Clin Immunol.1996;98:1088-96.
28. Ciprandi G, Pronzato C, Ricca V, Passalacqua G, Danzig M, Canonica GW. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. Clin Exp Allergy.1997;27:118-23.
29. Papi A, Papadopoulos N, Stanciu L, Degitz K, Holgate S, Johnston S. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. J Allergy Clin Immunol. 2001;108:221-8.
30. Michel L, Murrieta-Aguttes M, Jean-louis F, Levy D, Dubertret L. Humoral and cellular responses to histamine and pollen allergen in a skin chamber model: effect ofmizolastine. Ann Allergy Asthma Immunol. 2000;85:64-9.
31. Petecchia L, Serpero L, Silvestri M, Sabatini F, Scarso L, Rossi GA. The histamine-induced enhanced expression of vascular cell adhesion molecule-1 by nasal polyp-derived fibroblasts is inhibited by levocetirizine. Am J Rhinol. 2006;20:445-9.
32. Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther.1997;280:114-21.
33. Ciprandi G, Ricca V, Tosca M, Landi M, Passalacqua G, Canonica GW. Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. Allergy.1999; 54:358-65.
34. Ciprandi G, Passalacqua G, Mincarini M, Ricca V, Canonica GW. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol.1997;79:507-11.
35. Ciprandi G, Passalacqua G and Canonica GW. Effects of H1 antihistamines on adhesion molecules: a possible rationale for long-term treatment. Clin Exp Allergy.1999;29:49-53.
36. Pasquali M, Baiardini I, Rogkakou A, Riccio AM, Gamalero C, Descalzi D, Folli C, Passalacqua G, Canonica GW. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin Exp Allergy. 2006;36:1161-7.
37. Dizdar EA, Sekerel BE, Keskin O, Kalayci O, Adalioglu G, Dogan C, Tuncer A. The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis. Int J Pediatr Otorhinol-aryngol.2007;71(6):843-9.
38. Bauchau V and Durham S. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy. 2005;60:350-3.
39. Leong KP, Yeak SC, Saurajen AS, Mok PK, Earnest A, Siow JK, Chee NW, Yeo SB, Khoo ML, Lee JC, Seshadri R, Chan SP, Tang CY, Chng HH. Why generic and disease-specific quality-of-life instruments should be used together for the evaluation of patients with persistent allergic rhinitis. Clin Exp Allergy. 2005;35:288-98.
40. Passalacqua G and Baiardini I. Quality of life in allergic rhinitis. Clin Exp Allergy Rev. 2006;6:62-6.
41. Baiardini I, Pasquali M, Giardini A, Specchia C, Passalacqua G, Venturi S, Braido F, Bonini S, Majani G, Canonica GW. Rhinasthma: a new specific QoL questionnaire for patients with rhinitis and asthma. Allergy. 2003;58:289-94.
42. Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J, Van Cauwenberge PB, Van Hammee G: XPERT Study Group. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004;114:838-44.
43. De Vos C and Bachert C. Business and science: a partnership for the benefit of allergic patients. Clin Exp Allergy Rev. 2006;6:25-9.
44. Ciprandi G, Tosca M, Passalacqua G, Canonica GW. Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann Allergy Asthma Immunol. 2001;87:222-6.
45. Freche C, Leynadier F, Horak F, Hide D, Gracia FD, Goos M, Bachert C, Horvath A, Antosova E, Verrecchia M, Soussen PB. Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine. Ann Allergy Asthma Immunol. 2002;89:304-10.
46. Meltzer EO, Jalowayski AA, Vogt K, Iezzoni D, Harris AG. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol. 2006;96:363-8.
47. Hampel FJr, Howland W 3rd, Van Bavel J, Ratner P. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol. 2004;14:56-63.
48. Ratner P, Falques M, Chuecos F, Esbri R, Gispert J, Peris F, Luria X, Rosales MJ. Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis. Int Arch Allergy Immunol. 2005;138:312-8.
49. Martínez Cócera C, De Molina M, Martí Guadaño E, Pola J, Conde J, Borja J, Pérez I, Amaiz E, Izquierdo I: Spanish Rupatadine Rhinitis Study Group. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomized, double-blind paralel study. J Investig Allergol Clin Immunol. 2005;15:22-9.
50. Navarro AM. Rinitis. In: Alergológica 2005. Factores epidemiológicos, clínicos y socioeconómicos de las enfermedades alérgicas en España en 2005. 2006. p.107-31.
51. Ciprandi G, Frati F, Marcucci F, Sensi L, Milanese M, Tosca MA. Long-term cetirizine treatment may reduce new sensitizations in allergic childrIn: a pilot study. Allerg Immunol (Paris). 2003;35:208-11.
52. Riccioni G, Di Stefano F, De Benedictis M, Verna N, Cavallucci E, Paolini F, Di Sciascio MB, Della Vecchia R, Schiavone C, Boscolo P, Conti P, Di Gioacchino M. Seasonal variability of non-specific bronchial responsiveness in asthmatic patients with allergy to house dust mites. Allergy Asthma Proc. 2001;22:5-9.
53. Demoly P, Allaert FA, Lecasble M, Bousquet J. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy. 2003;58:672-5.
54. Riedl M and Díaz-Sánchez D. Biology of diesel exhaust effects on respiratory function. J Allergy Clin Immunol. 2005; 115:221-8.
55. Bernstein JA, Alexis N, Barnes C, Bernstein IL, Nel A, Peden D, Díaz-Sánchez D, Tarlo SM, Williams PB. Health effects of air polution. J Allergy Clin Immunol. 2004;114:1116-23.
56. Armentia A. Contenido alergénico de las gramíneas y polución. Alergol Inmunol Clin. 2003;18(Supl Num 3):97-101.
57. Schäppi GF, Suphioglu C, Taylor PE, Bruce Knox R. Concentrations of the major birch tree allergen Bet v1 in pollen and respirable fine particles in the atmosphere. J Allergy Clin Immunol.1997;100:656-61.
58. Simons FE. Advances in H1-antihistamines. N Eng J Med. 2004; 351:2207-17.
59. General discussion - Round-table meeting "The therapeutic index of antihistamines". Amsterdam, 5-6 May 1998. Allergy. 2000;55:62-9.
60. Holgate S, Canonica GW, Simons FE, Taglialatela M, Tharp M, Timmerman H, Yanai K. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 2003; 33:1305-24.
61. Warner J for the ETAC Study Group. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. J Allergy Clin Immunol. 2001;108:929-37.
62. Del Cuvillo A, Mullol J, Bartra J, Dávila I, Jáuregui I, Montoro J, Sastre J, Valero AL. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006;16(Suppl 1):3-12.
63. Dávila I, Sastre J, Bartra J, Del Cuvillo A, Jáuregui I, Montoro J, Mullol J, Valero AL. Effect of H1 antihistamines upon the cardiovascular system. J Investig Allergol Clin Immunol. 2006;16(Suppl 1):13-23.
64. Montoro J, Sastre J, Bartra J, Del Cuvillo A, Dávila I, Jáuregui I, Mullol J, Valero AL. Effect of H1 antihistamines upon the central nervous system. J Investig Allergol Clin Immunol. 2006;16(Suppl 1):24-8.
65. Bartra J, Valero A, Del Cuvillo A, Dávila I, Jáuregui I, Montoro J, Mullol J, Sastre J. Interactions of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006;16(Suppl 1):29-36.
66. Jáuregui I, Mullol J, Bartra J, Del Cuvillo A, Dávila I, Montoro J, Sastre J Valero AL. H1 antihistamines: psychomotor performance and driving. J Investig Allergol Clin Immunol. 2006;16(Suppl 1):37-44.